Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-α and p38 MAP kinase activity in rats after myocardial infarction

American Journal of the Medical Sciences

Volumn 340, Issue 2, 2010, Pages 121-127

  Xu, Yingying ^a   Tang, Tingting ^a   Ding, Yingjun ^a   Yao, Rui ^a   Xie, Jiangjiao ^a   Liao, Mengyang ^a   Xiao, Hong ^b   Chen, Yong ^a   Yu, Xian ^a   Fu, Michael ^c   Liao, Yuhua ^a   Zhao, Guanghong ^d   Cheng, Xiang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b No 1 Hospital of Wuhan   (China)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Acute myocardial infarction; Inflammation; P38 MAP kinase; Rosuvastatin; TNF

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; ROSUVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART PERFORMANCE; HEART VENTRICLE REMODELING; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; BLOOD; BLOOD PRESSURE; CHEMISTRY; HEART; HEART MUSCLE; HEART RATE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WISTAR RAT;

ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; CHOLESTEROL; ECHOCARDIOGRAPHY; FLUOROBENZENES; HEART; HEART RATE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIMIDINES; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR REMODELING;

EID: 77956019015     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181e2b353     Document Type: Article

References (36)

1. Liao YH, Cheng X. Autoimmunity in myocardial infarction. Int J Cardiol 2006;112:21-26
2. Ono K, Matsumori A, Shioi T, et al. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998;98:149-156
3. Thaik CM, Calderone A, Takahashi N, et al. Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995;96:1093-1099
4. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996;98: 2854-2865
5. Yue P, Massie BM, Simpson PC, et al. Cytokine expression increases in nonmyocyte from rats with postinfarction heart failure. Am J Physiol 1998;275(1 Pt 2):H250-8.
6. Geoghegan-Morphet N, Burger D, Lu X, et al. Role of neuronal nitric oxide synthase in lipopolysaccharide-induced tumor necrosis factoralpha expression in neonatal mouse cardiomyocytes. Cardiovasc Res 2007;75:408-416
7. Petrich BG, Wang Y. Stress-activated MAP kinases in cardiac remodeling and heart failure; new insights from transgenic studies. Trends Cardiovasc Med 2004;14:50-55
8. Boyle DL, Jones TL, Hammaker D, et al. Regulation of peripheral inflammation by spinal p38 MAP kinase in rats. PLoS Med 2006;3: e338.
9. Schieven GL. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem 2005;5:921-928
10. Shimizu N, Yoshiyama M, Omura T, et al. Activation of mitogenactivated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res 1998;38:116-124
11. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004;4:372-377
12. Lee JC, Kumar S, Griswold DE, et al. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000;47:185-201.
13. Kuma Y, Sabio G, Bain J, et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem 2005;280:19472-19479
14. Nahrendorf M, Hu K, Hiller KH, et al. Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study. J Am Coll Cardiol 2002;40: 1695-1700
15. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003;41:508-515
16. Landmesser U, Engberding N, Bahlmann FH, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004;110:1933-1939
17. Scalia R, Gooszen ME, Jones SP, et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 2001;103:2598-2603
18. Diomede L, Albani D, Sottocorno M, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001;21:1327-1332
19. Ley K, Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest 2001;107:1209-1210
20. Hilgendorff A, Muth H, Parviz B, et al. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther 2003;41:397-401.
21. Zhang J, Cheng X, Liao YH, et al. Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction. Cardiovasc Drugs Ther 2005;19: 13-21. (Pubitemid 40767768)
22. Kim YS, Ahn Y, Hong MH, et al. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and nuclear factor-kappaB in endothelial cells. J Cardiovasc Pharmacol 2007;49:376-383
23. Cheng X, Liao YH, Ge H, et al. TH1/TH2 functional imbalance after acute myocardial infarction: coronary arterial inflammation or myocardial inflammation. J Clin Immunol 2005;25:246-253
24. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87:28-32.
25. Litwin SE, Katz SE, Morgan JP, et al. Long-term captopril treatment improves diastolic filling more than systolic performance in rats with large myocardial infarction. J Am Coll Cardiol 1996; 28:773-781
26. Nian M, Lee P, Khaper N, et al. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004;94:1543-1553
27. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factoralpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-711
28. Otsu K, Yamashita N, Nishida K, et al. Disruption of a single copy of the p38alpha MAP kinase gene leads to cardioprotection against ischemia- reperfusion. Biochem Biophys Res Commun 2003;302: 56-60.
29. Lee TM, Lin MS, Chou TF, et al. Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005;289:H220-7.
30. Hayashidani S, Tsutsui H, Shiomi T, et al. Fluvastatin, a 3-hydroxy- 3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;105:868-873 (Pubitemid 34174929)
31. Ohara Y, Hiasa Y, Hosokawa S, et al. Impact of hydroxymethylglutaryl coenzyme A reductase inhibition on left ventricular remodeling in patients with acute anterior myocardial infarction after primary coronary angioplasty. Int Heart J 2005;46:987-995
32. Lansberg P. Pleiotropic effects of statins and beyond. Cardiology 2009;112:1-3.
33. Zacà V, Rastogi S, Imai M, et al. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2007;50:551-557 (Pubitemid 47126770)
34. Chen LL, Zhu TB, Yin H, et al. Inhibition of MAPK signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through reduction of inflammation [published online ahead of print November 12, 2009]. Mol Biol Rep. doi: 10.1007/ s11033-009-9879-9886
35. Yan G, You B, Chen SP, et al. Tumor necrosis factor-alpha downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-alpha 1. Circ Res 2008;103:591-597
36. Agnoletti L, Curello S, Bachetti T, et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation 1999;100:1983-1991